mNEXSPIKE

all catalysts(0)

nothing on the calendar yet

News(3)

• BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
  Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The news follows Merck and Moderna’s Phase…
  biospace · 1mo ago
• Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
  Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.
  biopharma_dive · 1mo ago
• Moderna maintains 10% growth target despite Phase 3 norovirus miss
  Moderna’s norovirus vaccine failed in a Phase 3 trial, but the company still has faith in an ambitious revenue growth target thanks to ex-U.S. vaccine sales and a unanimous FDA adcomm win for mFLUS…
  biospace · 2mo ago